Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084859 | 0.87 | AOC3 (0.55) | AOC3SMN1; SMN2KMT2ATYRLMNA | |
| SCHEMBL13045057 | 0.86 | AOC3 (0.54) | AOC3SMN1; SMN2KMT2ATYRLMNA | |
| SCHEMBL18997031 | 0.83 | AOC3 (0.52) | AOC3SMN1; SMN2KMT2ATYRLMNA | |
| SCHEMBL3933173 | 0.81 | SMN1; SMN2 (0.73) | AOC3SMN1; SMN2KMT2ALMNACCNE1 | |
| SCHEMBL465934 | 0.80 | SMN1; SMN2 (0.51) | AOC3SMN1; SMN2KMT2ALMNAPDE5A | |
| SCHEMBL20935426 | 0.79 | GAA (0.49) | SMN1; SMN2KMT2ALMNAPDE5ASCD | |
| SCHEMBL24595147 | 0.79 | SMN1; SMN2 (0.51) | AOC3SMN1; SMN2KMT2ALMNAPDE5A | |
| SCHEMBL8251195 | 0.79 | AOC3 (0.69) | AOC3KMT2APDE5AMMEMEN1 | |
| SCHEMBL9570949 | 0.78 | MAPT (0.60) | SMN1; SMN2KMT2ATYRLMNAGAA | |
| SCHEMBL27944093 | 0.78 | TYR (0.57) | AOC3SMN1; SMN2KMT2ATYRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1761655-A | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1587800-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | Astellas Pharma Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163219-A1 | HCV Protease Inhibitors | CPN1, CTRL, CTSZ | AOC3 140/4885SMN1; SMN2 3891/4885KMT2A 1836/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AOC3 85/4885SMN1; SMN2 3587/4885KMT2A 3324/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885SMN1; SMN2 966/4885KMT2A 4395/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | AOC3 590/4885SMN1; SMN2 1570/4885KMT2A 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.